A Phase 2/3 interventional study of preemptive mefenamic acid and mefenamic acid in Primary Dysmenorrhea, sponsored by Hanan Nabil. Completed at 1 site in Egypt. Open to female participants aged 15 Years to 25 Years. Per ClinicalTrials.gov, last updated 2017-12-19.
Sponsored by Hanan Nabil · Phase 2/3, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Dysmenorrhea with a site in Egypt — 13 open to participants now, 13 under way, none of them phase 3. Dysmenorrhea · Egypt.
Among the 37 studies in Dysmenorrhea with a site in Egypt, this one is the 6th largest by enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2017, is the only one in phase 2/3, and was the 1st registered.
432 studies on the registry are indexed under Dysmenorrhea; 109 are open to participants now.
Browse Dysmenorrhea studies →13 of the 37 studies in Dysmenorrhea with a site in Egypt are open now. Recruiting first, the newest first:
Al Hayah University In Cairo · Sites in Egypt
Ages 18–23 · Women only
Kafrelsheikh University · Sites in Egypt
Ages 20–25 · Women only
Cairo University · Sites in Egypt
Ages 18–25 · Women only · Healthy volunteers
Cairo University · Sites in Egypt
Ages 18–25 · Women only
New Ismailia National University · Sites in Egypt, Jordan
Ages 13–20 · Women only · Healthy volunteers
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 59 Dysmenorrhea studies recruiting now, 7 (12%) set no upper age limit and 51 (86%) stop at 75 or younger; 11 take children under 18; 20 take healthy volunteers.
This study: 15 Years to 25 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 84 is above the median of 62 across 364 interventional studies indexed under Dysmenorrhea.
Median enrollment 58 across the 25 interventional studies, 78 across the 12 observational. Of the 23 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 37 has an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Hanan Nabil as lead sponsor.
Hanan Nabil has 1 study filed under Dysmenorrhea — fewer than ten, so there is no comparison to draw.
1 of the studies in Dysmenorrhea with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07935668Al Hayah University In CairoAssociation Between Menstrual Pain Severity and Plantar Pressure in Young Women | 2027-02-01 |
Add it to your calendar (.ics) → With an account.
Among the 37 studies in Dysmenorrhea with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Preemptive analgesia before the release of pain mediators
spasmodic dysmenorrhea is one of the most distressing symptoms in women. adolescents shows a usual absence from school . prostaglandin release is one of the most accepted theory responsible for spasmodic dysmenorrhea.
Non steroidal anti inflammatory Drugs were proved to be one of the alternative medications for spasmodic dysmenorrhea.
Getting the idea of what is called preemptive anesthesia by blocking the receptors before catching pain mediators the study participants will be divided randomly into 2 group group 1 receiving ttt 2 days before the anticipated menstruation and group 2 receiving ttt only during menstruation as analgesia
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
preemptive mefenamic acid 500mg tablets every 8 hours starting 2 days before anticipated menstruation and during the first 2 days of the cycle
Drug: preemptive mefenamic acid
mefenamic acid 500mg tablets every 8 hours during the first 2 days of the cycle
Drug: mefenamic acid
preemptive analgesia before menstrual pain
Also known as: ponstan forte
mefenamic acid given only during menstruation
Also known as: ponstan forte
change in the Degree of pain
severity of pain according to visual pain analog scale
Time frame: 4 months
Ran from Aug 2017 to primary completion in Dec 2017, 4 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mefenamic Acid